我们是否忽视了老年患者的治疗失败?
本文是一篇截至2024年6月的叙述性综述,聚焦老年患者三种药物不良事件中较少被识别的治疗失败(TF)。综述仅找到16项评估老年TF的研究,TF中位发生率7.4%,多数被认为可预防,常见原因为用药不依从和必要药物处方不足。作者强调在关注减药与多重用药的同时不应忽视TF这一重要且多可预防的伤害来源。
要点
- 老年患者TF中位发生率7.4%,多数可预防,常见原因为用药不依从与必要药物处方不足。
- 自1991年首次描述TF以来仅16项研究评估老年TF,且研究设计较弱、样本较小。
- 仅5项研究使用已在评分者间信度上表现良好的治疗失败问卷(TFQ)这一隐性工具。
核心结论
- 治疗失败是老年患者中重要且以可预防为主的药物不良事件来源,临床不应只关注减药与多重用药。
- 治疗失败会延长住院时间、促进疾病持续、降低生活质量并增加疾病社会成本。
- 需要更多最新的稳健观察性研究来进一步理解治疗失败对老年患者经济与人文结局的影响。
研究设计与样本
- 叙述性综述,检索截至2024年6月的医学文献,汇总相关文章并讨论循证方法与未来研究方向。
- 综述共识别出16项评估老年患者治疗失败的研究。
主要发现
- 16项研究中治疗失败的中位发生率为7.4%,多数治疗失败被认为可预防。
- 该人群治疗失败的常见原因包括用药不依从和必要药物处方不足。
- 这些研究存在观察性设计较弱、样本相对较小、可能无法外推至全部老年人群等局限。
- 仅5项研究使用了治疗失败问卷(TFQ)这一隐性工具,该工具已被证明具有良好评分者间信度。
关键数值与推荐
- 治疗失败中位发生率7.4%(基于综述识别的16项研究)。
- 仅5项研究使用治疗失败问卷(TFQ)评估治疗失败。
临床怎么用
- 临床医生在处理老年药物不良事件时,除减药和减少多重用药外,还应识别和防范治疗失败。
- 评估治疗失败时应关注用药不依从与必要药物处方不足这两类常见可预防原因。
局限性
- 所汇总研究多为弱观察性设计且样本相对较小,结果可能无法推广至全部老年人群。
- 仅少数研究使用信度良好的隐性工具(TFQ),治疗失败识别方法有限。
- 自1991年首次描述治疗失败以来相关研究数量少,证据仍不充分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Three types of adverse drug events have been identified in studies of medication-related harms among older adults: adverse drug reactions, adverse drug withdrawal events, and therapeutic failures (TFs). METHODS: In this narrative review of medical literature through June 2024, we summarize relevant articles and discuss evidence-based approaches and opportunities for future research to address TFs, as they are lesser recognized adverse drug events. RESULTS: Despite more than three decades elapsing since TF was first described in 1991, we identified only 16 studies in our review that evaluated TF in older adults. The median rate of TFs among these 16 studies was 7.4%, and most TFs were considered preventable. Common reasons for TF in this population included medication nonadherence and underprescribing of necessary medications. These studies share several limitations, including weak observational study designs and relatively small samples that may not generalize to all populations of older adults. Finally, only five studies utilized an implicit tool (the Therapeutic Failure Questionnaire) that has been shown to have good interrater reliability. CONCLUSIONS: We acknowledge that clinicians should, and often do, attend first to deprescribing and reducing polypharmacy in managing adverse drug reactions among older adults. We must not forget, however, about TFs as an important and predominantly preventable source of harm among our older adult patients. TFs increase the length of hospital stays, promote disease persistence, reduce quality of life, and increase social costs of disease. We believe TFs remain a prevalent and important problem in older adults. More data are needed from up-to-date robust observational studies to further understand the impact of TFs on economic and humanistic outcomes in older adults.
引用
- Naples JG, Aspinall SL, Schmader K, et al. Have We Forgotten About Therapeutic Failure in Older Adults? J Am Geriatr Soc. 2025. PMID: 40302227. doi:10.1111/jgs.19497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。